Carolina Biooncology

Huntersville, North Carolina 28708

2 studies enrolling now · 14 studies all time

What they study most

Acral Lentiginous Melanoma, Advanced Solid Tumor, Advanced Solid Tumor or Lymphoma, Advanced Solid Tumors, Breast Cancer, Cancer, Castration-Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, DMMR Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Squamous Cell Cancer

Studies at this site

• A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors — Recruiting now
• A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors — Stopped early
• A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors — Running, not enrolling
• A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 — Enrolling by invitation
• Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors — Stopped early
• A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors — Stopped early
• A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors — Completed
• Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies — Completed
• Safety and Tolerability of Intravenous Administration of ICVB-1042 — Stopped early
• Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 — Stopped early
• Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors — Completed
• A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies — Stopped early
• A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma — Status unconfirmed
• Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors — Status unconfirmed